Arcus Biosciences Inc (RCUS)
Total asset turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 258,000 | 117,000 | 112,000 | 382,882 | 77,517 |
| Total assets | US$ in thousands | 1,150,000 | 1,095,000 | 1,345,000 | 1,592,000 | 772,292 |
| Total asset turnover | 0.22 | 0.11 | 0.08 | 0.24 | 0.10 |
December 31, 2024 calculation
Total asset turnover = Revenue ÷ Total assets
= $258,000K ÷ $1,150,000K
= 0.22
In analyzing Arcus Biosciences Inc's total asset turnover over the past five years, we observe fluctuating trends. The total asset turnover ratio measures a company's efficiency in generating sales revenue from its total assets.
The total asset turnover ratio stood at 0.10 as of December 31, 2020, indicating that the company generated $0.10 in sales for every dollar of total assets during that period.
In the subsequent year, the ratio saw a significant improvement, reaching 0.24 by December 31, 2021. This signifies a boost in efficiency, with the company generating $0.24 in sales for each dollar of total assets.
However, the ratio dipped to 0.08 by December 31, 2022, suggesting a decline in the efficiency of asset utilization in generating sales revenue. This could be an area of concern for stakeholders.
The following year, the total asset turnover ratio improved slightly to 0.11 as of December 31, 2023. While there was a modest recovery, the ratio still remained below the levels seen in 2021.
By the end of December 31, 2024, the total asset turnover ratio had increased to 0.22, indicating a significant improvement in asset utilization efficiency compared to the previous year. This suggests that the company was able to generate $0.22 in sales for every dollar of total assets during that period.
Overall, the total asset turnover ratio for Arcus Biosciences Inc has exhibited variability over the past five years, with notable fluctuations in efficiency levels. Stakeholders may need to monitor this ratio closely to assess the company's ability to effectively utilize its assets in generating sales revenue.
Peer comparison
Dec 31, 2024